Distinguishing Prostate Cancer from BPH

Key Clinical Distinguishing Features

A nodular or hard prostate on digital rectal examination carries approximately 50% probability of prostate cancer on biopsy, making this the single most important physical finding to distinguish cancer from BPH, according to the American Urological Association 2
Digital rectal examination combined with PSA is superior to either test alone for differentiating these conditions, as recommended by the American Urological Association 2, 5
PSA elevation alone is insufficient to distinguish BPH from cancer, as both conditions elevate PSA, and the American Urological Association suggests considering PSA density and other factors 1, 6
PSA density (PSA divided by prostate volume) >0.15 ng/ml/cc strongly suggests cancer over BPH, particularly in smaller prostates, according to the European Association of Urology 3
Men with elevated PSA and lower urinary tract symptoms have lower risk of prostate cancer compared to men with elevated PSA without symptoms, as symptoms typically indicate BPH, and this is supported by the American Urological Association 2, 4

The American Urological Association recommends proceeding directly to biopsy discussion when there are high-risk features such as abnormal digital rectal examination, PSA >10 ng/ml, PSA density >0.15 ng/ml/cc, African American ethnicity with any PSA elevation, first-degree relative with prostate cancer, or persistently elevated PSA without urinary symptoms 1, 2, 3, 6
The European Association of Urology suggests considering multiparametric MRI before biopsy when there are intermediate-risk features such as PSA 3-10 ng/ml with normal digital rectal examination, equivocal digital rectal examination findings, or PSA density 0.10-0.15 ng/ml/cc 3, 5, 6
MRI has 91% sensitivity for clinically significant cancer (ISUP grade ≥2) and can help avoid unnecessary biopsies, according to the European Association of Urology 3

The American Urological Association recommends beginning baseline PSA testing at age 40 in well-informed men to establish risk stratification for future screening, with a moderate level of evidence 1, 6
Men with <10-15 years life expectancy are unlikely to benefit from prostate cancer diagnosis, making BPH the primary consideration in this population, and this is supported by the European Association of Urology with a low level of evidence 3
PSA is more specific for cancer in younger men (<50 years) because prostatic enlargement is less likely to confound interpretation, according to the American Urological Association with a high level of evidence 1, 6